Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer

Insulin and insulin-like growth factor (IGF) signaling system, commonly known for fine-tuning numerous biological processes, has lately made its mark as a much sought-after therapeutic targets for diabetes and cancer. These receptors make an attractive anticancer target owing to their overexpression in variety of cancer especially in prostate and breast cancer. Inhibitors of IGF signaling were subjected to clinical cancer trials with the main objective to confirm the effectiveness of these receptors as a therapeutic target. However, the results that these trials produced proved to be disappointing as the role played by the cross talk between IGF and insulin receptor (IR) signaling pathways at the receptor level or at downstream signaling level became more lucid. Therapeutic strategy for IGF-1R and IR inhibition mainly encompasses three main approaches namely receptor blockade with monoclonal antibodies, tyrosine kinase inhibition (ATP antagonist and non-ATP antagonist), and ligand neutralization via monoclonal antibodies targeted to ligand or recombinant IGF-binding proteins. Other drug-discovery approaches are employed to target IGF-1R, and IR includes antisense oligonucleotides and recombinant IGF-binding proteins. However, therapies with monoclonal antibodies and tyrosine kinase inhibition targeting the IGF-1R are not evidenced to be satisfactory as expected. Factors that are duly held responsible for the unsuccessfulness of these therapies include (a) the existence of the IR isoform A overexpressed on a variety of cancers, enhancing the mitogenic signals to the nucleus leading to the endorsement of cell growth, (b) IGF-1R and IR that form hybrid receptors sensitive to the stimulation of all three IGF axis ligands, and (c) IGF-1R and IR that also have the potential to form hybrid receptors with other tyrosine kinase to potentiate the cellular transformation, tumorigenesis, and tumor vascularization. This mini review is a concerted effort to explore and fathom the well-recognized roles of the IRA signaling system in human cancer phenotype and the main strategies that have been so far evaluated to target the IR and IGF-1R.

[1]  A. Belfiore,et al.  The IGF system in thyroid cancer: new concepts , 2001, Molecular pathology : MP.

[2]  Zheng Yang,et al.  BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR , 2009, Molecular Cancer Therapeutics.

[3]  S. Keir,et al.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[4]  A. Brunetti,et al.  Regulating Insulin-Receptor-Gene Expression by Differentiation and Hormones , 1990, Diabetes Care.

[5]  D. Yee,et al.  Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor , 2012, Breast Cancer Research and Treatment.

[6]  Siegal Sadetzki,et al.  Diabetes mellitus and breast cancer. , 2005, The Lancet. Oncology.

[7]  R. Baxter.  Insulin-like growth factor binding proteins in the human circulation: a review. , 1994, Hormone research.

[8]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[9]  C. Duan,et al.  Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. , 2005, General and comparative endocrinology.

[10]  G. Colditz,et al.  Obesity and Cancer , 2010, The oncologist.

[11]  C. Conover,et al.  In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. , 2006, Cancer research.

[12]  Wei Zhu,et al.  Altered Expression of Insulin Receptor Isoforms in Breast Cancer , 2011, PloS one.

[13]  J. Droz,et al.  Insulin-Like Growth Factor (IGF) family and prostate cancer. , 2006, Critical reviews in oncology/hematology.

[14]  M. Wiedmann,et al.  Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. , 2010, World journal of gastroenterology.

[15]  F. Huang,et al.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. , 2011, Cancer research.

[16]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[17]  M. Pollak,et al.  IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. , 2011, Endocrine-related cancer.

[18]  David Cunningham,et al.  Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. , 2009, Recent patents on anti-cancer drug discovery.

[19]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[20]  M. Pollak,et al.  Insulin-like growth factors and prostate cancer. , 2001, Epidemiologic reviews.

[21]  Francesco Hofmann,et al.  Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. , 2005, Drug discovery today.

[22]  Anne-Marie Cleton-Jansen,et al.  IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma , 2013, BMC Cancer.

[23]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[25]  J. Bourhis,et al.  Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer , 2007, Nature Clinical Practice Oncology.

[26]  K. Siddle,et al.  Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. , 1986, The Biochemical journal.

[27]  C. Korch,et al.  Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development , 2010, Clinical Cancer Research.

[28]  A. Belfiore,et al.  Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. , 2012, Endocrinology.

[29]  G. Booker,et al.  Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. , 2004, Molecular endocrinology.

[30]  G. Hammer,et al.  Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma , 2010, Cancer Chemotherapy and Pharmacology.

[31]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[32]  A. Levitzki,et al.  Tyrphostins and other tyrosine kinase inhibitors. , 2006, Annual review of biochemistry.

[33]  Peter Bohlen,et al.  Di-diabody: a novel tetravalent bispecific antibody molecule by design. , 2003, Journal of immunological methods.

[34]  C. Busch,et al.  Significant expression of IGFBP2 in breast cancer compared with benign lesions , 2005, Journal of Clinical Pathology.

[35]  K. Wong,et al.  Insulin-like growth factor: current concepts and new developments in cancer therapy. , 2012, Recent patents on anti-cancer drug discovery.

[36]  RolandEKONTERMANN.  Recombinant bispecific antibodies for cancer therapy , 2005 .

[37]  D. Leroith,et al.  Insulin and Insulin-Like Growth Factor I Receptors: Similarities and Differences in Signal Transduction , 2004, Hormone Research in Paediatrics.

[38]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[39]  E. K. Maloney,et al.  An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. , 2003, Cancer research.

[40]  F. Frasca,et al.  The role of insulin receptors and IGF-I receptors in cancer and other diseases. , 2008, Archives of physiology and biochemistry.

[41]  向原 徹.  Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression , 2011 .

[42]  C. Dominici,et al.  Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo , 2006, Clinical Cancer Research.

[43]  Xia Han,et al.  The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. , 2009, Cancer research.

[44]  Richard Gorlick,et al.  Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program , 2011, Pediatric blood & cancer.

[45]  O. Larsson,et al.  Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications , 2011, International journal of oncology.

[46]  F. J. Ramos,et al.  A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Yee,et al.  Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. , 2007, Cancer research.

[48]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[49]  P. H. Hansen,et al.  Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[51]  M. Hixon,et al.  Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. , 2010, Reviews on recent clinical trials.

[52]  F. Esteva,et al.  Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[53]  F. Hofmann,et al.  The insulin‐like growth factor‐I receptor inhibitor NVP‐AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells , 2008, British Journal of Haematology.

[54]  D. Yee,et al.  A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. , 2003, Cancer research.

[55]  G. Booker,et al.  Molecular interactions of the IGF system. , 2005, Cytokine & growth factor reviews.

[56]  A. Davoodi-Semiromi,et al.  The Tyrphostin Agent AG490 Prevents and Reverses Type 1 Diabetes in NOD Mice , 2012, PloS one.

[57]  Chiehying Y Chang,et al.  Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. , 2005, Journal of medicinal chemistry.

[58]  E. Ozkan.  Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review , 2011, Molecular and Cellular Endocrinology.

[59]  C. Nanni,et al.  Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.

[60]  A. Belfiore,et al.  Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved* , 2002, The Journal of Biological Chemistry.

[61]  P. Opolon,et al.  Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. , 2010, European journal of cancer.

[62]  P. Nelson,et al.  Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors , 2006, Clinical Cancer Research.

[63]  D. Ludwig,et al.  Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis , 2006, Cancer Immunology, Immunotherapy.

[64]  B. Blagoev,et al.  Agonism and Antagonism at the Insulin Receptor , 2012, PloS one.

[65]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[66]  P. Pisani.  Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. , 2008, Archives of physiology and biochemistry.

[67]  A. Yasmeen,et al.  BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. , 2009, Gynecologic oncology.

[68]  L. Glodé.  Metabolic syndrome and prostate cancer , 2008, Cancer.

[69]  W. Yung,et al.  Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. , 1999, Cancer research.

[70]  P. Bhosale,et al.  Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. , 2010 .

[71]  F. Huang,et al.  Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. , 2010, Endocrinology.

[72]  J. McCubrey,et al.  The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion , 2007, Leukemia.

[73]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[74]  V. Hwa,et al.  The Insulin-like Growth Factor-binding Protein (igfbp) Superfamily* , 2022 .

[75]  S. Kihara,et al.  Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[76]  E. Monti,et al.  The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. , 2010, Biochemical pharmacology.

[77]  Robert H. Bell,et al.  Insulin receptor expression by human prostate cancers , 2009, The Prostate.

[78]  D. Yee,et al.  Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo , 2009, Clinical Cancer Research.

[79]  A. Thorburn,et al.  The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models , 2010, Clinical Cancer Research.

[80]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[81]  N. Nguyen,et al.  Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. , 2008, Journal of the American College of Surgeons.

[82]  H. Boezen,et al.  The insulin-like growth factor 1 receptor in cancer: old focus, new future. , 2007, European journal of cancer.

[83]  S. Bonovas,et al.  Diabetes mellitus and risk of prostate cancer: a meta-analysis , 2004, Diabetologia.

[84]  G. Scagliotti,et al.  The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. , 2012, Cancer treatment reviews.

[85]  T. Issad,et al.  Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2 , 2012, PloS one.

[86]  D. Yee,et al.  The therapeutic potential of agents targeting the type I insulin-like growth factor receptor , 2004, Expert opinion on investigational drugs.

[87]  M. Heni,et al.  Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer , 2012, PloS one.

[88]  H. Waldmann,et al.  Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. , 2003, Journal of medicinal chemistry.

[89]  M. Pollak,et al.  Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[90]  P. Picci,et al.  Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. , 2005, European journal of cancer.

[91]  K. Siddle,et al.  Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[93]  G. Trainor,et al.  Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one. , 2010, Bioorganic & medicinal chemistry letters.

[94]  S. Soegondo.  Atherogenic dyslipidemia and the metabolic syndrome. , 2005, Acta medica Indonesiana.

[95]  D. Loegering,et al.  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. , 2009, Cancer research.

[96]  S. Avnet,et al.  Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. , 2009, Cancer research.

[97]  Yan Wang,et al.  Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[98]  D. Ludwig,et al.  IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor , 2007, Clinical Cancer Research.

[99]  K. Shitara,et al.  Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors , 2004, Cancer Research.

[100]  G. Trainor,et al.  Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. , 2009, Journal of medicinal chemistry.

[101]  D. Yee,et al.  Inhibition of Cancer Cell Proliferation and Metastasis by Insulin Receptor Downregulation , 2010, Oncogene.

[102]  H. Adami,et al.  Risk of endometrial and breast cancer in patients with diabetes mellitus , 1997, International journal of cancer.

[103]  A. Levitzki,et al.  Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. , 1991, Journal of medicinal chemistry.

[104]  J. Whittaker,et al.  Structural biology of insulin and IGF1 receptors: implications for drug design , 2002, Nature Reviews Drug Discovery.

[105]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[106]  A. Nishiyama,et al.  Aldosterone Induces Vascular Insulin Resistance by Increasing Insulin-Like Growth Factor-1 Receptor and Hybrid Receptor , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[107]  O. Larsson,et al.  Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. , 2006, Blood.

[108]  M. Mcdaniel,et al.  Insulin Mediates Glucose-stimulated Phosphorylation of PHAS-I by Pancreatic Beta Cells , 1998, The Journal of Biological Chemistry.

[109]  S. Mok,et al.  The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. , 2011, Gynecologic oncology.

[110]  A. Gualberto,et al.  Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions , 2009, Oncogene.

[111]  Francesco Hofmann,et al.  PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. , 2010, Neuro-oncology.

[112]  Y. Naomoto,et al.  IGF-IR and its inhibitors in gastrointestinal carcinomas (Review). , 2010, Oncology letters.

[113]  E. Giovannucci,et al.  A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[114]  O. Stoeltzing,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. , 2008, European journal of cancer.

[115]  J. McCubrey,et al.  Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts , 2007, Leukemia.

[116]  S. Koujak,et al.  Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer , 2010, Molecular Cancer Therapeutics.

[117]  S. Schuetze,et al.  Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. , 2010, The Lancet. Oncology.

[118]  A. Yasmeen,et al.  Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer , 2010, Journal of oncology.

[119]  E. McKinley,et al.  18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer , 2011, Clinical Cancer Research.

[120]  M. Bergqvist,et al.  Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma , 2011, Acta oncologica.

[121]  Laura Sciacca,et al.  Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. , 2009, Endocrine reviews.

[122]  T. Issad,et al.  Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. , 2008, Biochemical pharmacology.

[123]  L. Lipton,et al.  Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. , 2010 .

[124]  A. Gualberto,et al.  Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. , 2009, Clinical lung cancer.

[125]  S. Chua,et al.  Obesity, metabolic syndrome, and prostate cancer. , 2007, The American journal of clinical nutrition.

[126]  J. Baselga,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[127]  W. Fisher.  Diabetes: Risk Factor for the Development of Pancreatic Cancer or Manifestation of the Disease? , 2001, World Journal of Surgery.

[128]  Helen X. Chen,et al.  Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors , 2012, Clinical Cancer Research.

[129]  A. Martins,et al.  Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor , 2006, Clinical Cancer Research.

[130]  R. Kurzrock,et al.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials , 2008, Molecular Cancer Therapeutics.

[131]  D. Flieder,et al.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.

[132]  H. Grosse.  [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.

[133]  Sergey M Deyev,et al.  Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[134]  S. Grundy.  Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. , 1998, The American journal of cardiology.

[135]  D. Yee,et al.  Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.

[136]  J. Fargnoli,et al.  Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. , 2010, Cancer research.

[137]  P. Lollini,et al.  Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. , 2005, Cancer research.

[138]  M. Ladanyi,et al.  Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature , 2013, Sarcoma.

[139]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. , 2003, Cancer research.

[140]  T. Rohan,et al.  The relation of type 2 diabetes and cancer. , 2001, Diabetes technology & therapeutics.

[141]  B. Leyland-Jones,et al.  Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. , 2006, Cancer research.

[142]  J. Sturis,et al.  A novel high-affinity peptide antagonist to the insulin receptor. , 2008, Biochemical and biophysical research communications.

[143]  H. Werner,et al.  Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways , 2008, Archives of Physiology and Biochemistry.

[144]  R. Kuick,et al.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[145]  P. Baumann,et al.  Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001 , 2009, Anti-cancer drugs.

[146]  M. Ohtani,et al.  Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells. , 2009, Bioscience trends.

[147]  W. R. Bishop,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody , 2005, Molecular Cancer Therapeutics.

[148]  K. Shitara,et al.  Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers , 2005, Clinical Cancer Research.

[149]  J. Dupont,et al.  Biology of insulin-like growth factors in development. , 2003, Birth defects research. Part C, Embryo today : reviews.

[150]  J. Manola,et al.  Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors , 2010, Clinical Cancer Research.

[151]  D. Yee,et al.  Combined Effects of Tamoxifen and a Chimeric Humanized Single Chain Antibody against the Type I IGF Receptor on Breast Tumor Growth In vivo , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[152]  G. Calin,et al.  Circulating microRNAs as noninvasive biomarkers in breast cancer. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[153]  O. Larsson,et al.  Uveal Melanoma and Macular Degeneration: Molecular Biology and Potential Therapeutic Applications the Insulin-like Growth Factor-i Receptor Inhibitor Picropodophyllin Causes Tumor Regression and Attenuates Mechanisms Involved in Invasion of Uveal Melanoma Cells , 2022 .

[154]  N. Gibson,et al.  Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. , 2009, Future medicinal chemistry.

[155]  A. Vikram,et al.  S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats. , 2010, Biochemical and biophysical research communications.

[156]  A. Wu,et al.  Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth , 2000, Cancer Immunology, Immunotherapy.